SVEP1 enables efficient binding of Angiopoietin-2 to the TIE1 receptor, allowing receptor phosphorylation and downstream signaling Article Swipe

PDF

Katharina Uphoff , Melina Hußmann , Dörte Schulte-Ostermann , Yvonne Huisman , Matthias Mörgelin , Fabian Metzen , Fernando Bazán , Manuel Koch , Stefan Schulte‐Merker ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1101/2025.03.17.643633

The molecular mechanisms that drive (lymph-)angiogenesis are crucial to understand diseases, such as lymphedema, that are caused due to malformations of the lymphatic vasculature. Recently an interaction between the secreted protein Svep1, a key regulator in lymphangiogenesis, and the transmembrane receptor Tie1 was shown in zebrafish, human and mice. Here, guided by in silico AlphaFold-multimer structure predictions of highly confident SVEP1 complexes, we assert with protein binding studies that the human CCP20 domain is the primary binding site for TIE1, and also show that in addition the CCP5-EGFL7 fragment of SVEP1 engages TIE1 as a secondary site. We further demonstrate that SVEP1 mediates strong binding of ANG2 and TIE1, and that combined stimulation of hdLECs with SVEP1 and ANG2 leads to phosphorylation of TIE1. TIE1 activation by SVEP1 and ANG2 enables downstream signaling and in turn potentiates nuclear exclusion of FOXO1 and phosphorylation of AKT compared to SVEP1 or ANG2 alone. We present a model where ANG1/2 dimers bind to both SVEP1 and TIE1, resulting in multiple TIE1 receptor molecules being recruited to a multimeric complex at the cell membrane, potentially amplifying its signaling capacity.

Related Topics

Concepts

Downstream (manufacturing) Cell biology Phosphorylation Receptor Angiopoietin 2 Chemistry Biology Business Biochemistry Cancer research VEGF receptors Marketing Vascular endothelial growth factor

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1101/2025.03.17.643633
PDF: https://www.biorxiv.org/content/biorxiv/early/2025/03/20/2025.03.17.643633.full.pdf
OA Status: green
References: 34
Related Works: 10
OpenAlex ID: https://openalex.org/W4408742069

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4408742069

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1101/2025.03.17.643633

Digital Object Identifier
Title: SVEP1 enables efficient binding of Angiopoietin-2 to the TIE1 receptor, allowing receptor phosphorylation and downstream signaling

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-03-20

Full publication date if available
Authors: Katharina Uphoff, Melina Hußmann, Dörte Schulte-Ostermann, Yvonne Huisman, Matthias Mörgelin, Fabian Metzen, Fernando Bazán, Manuel Koch, Stefan Schulte‐Merker

List of authors in order
Landing page: https://doi.org/10.1101/2025.03.17.643633

Publisher landing page
PDF URL: https://www.biorxiv.org/content/biorxiv/early/2025/03/20/2025.03.17.643633.full.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: green

Open access status per OpenAlex
OA URL: https://www.biorxiv.org/content/biorxiv/early/2025/03/20/2025.03.17.643633.full.pdf

Direct OA link when available
Concepts: Downstream (manufacturing), Cell biology, Phosphorylation, Receptor, Angiopoietin 2, Chemistry, Biology, Business, Biochemistry, Cancer research, VEGF receptors, Marketing, Vascular endothelial growth factor

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
References (count): 34

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4408742069
doi	https://doi.org/10.1101/2025.03.17.643633
ids.doi	https://doi.org/10.1101/2025.03.17.643633
ids.openalex	https://openalex.org/W4408742069
fwci	0.0
type	preprint
title	SVEP1 enables efficient binding of Angiopoietin-2 to the TIE1 receptor, allowing receptor phosphorylation and downstream signaling
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T10422
topics[0].field.id	https://openalex.org/fields/13
topics[0].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[0].score	0.9902999997138977
topics[0].domain.id	https://openalex.org/domains/1
topics[0].domain.display_name	Life Sciences
topics[0].subfield.id	https://openalex.org/subfields/1312
topics[0].subfield.display_name	Molecular Biology
topics[0].display_name	Angiogenesis and VEGF in Cancer
topics[1].id	https://openalex.org/T12955
topics[1].field.id	https://openalex.org/fields/24
topics[1].field.display_name	Immunology and Microbiology
topics[1].score	0.9750000238418579
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/2403
topics[1].subfield.display_name	Immunology
topics[1].display_name	Atherosclerosis and Cardiovascular Diseases
topics[2].id	https://openalex.org/T10831
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9717000126838684
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2723
topics[2].subfield.display_name	Immunology and Allergy
topics[2].display_name	Cell Adhesion Molecules Research
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2776207758
concepts[0].level	2
concepts[0].score	0.7079275250434875
concepts[0].wikidata	https://www.wikidata.org/wiki/Q5303302
concepts[0].display_name	Downstream (manufacturing)
concepts[1].id	https://openalex.org/C95444343
concepts[1].level	1
concepts[1].score	0.6655499935150146
concepts[1].wikidata	https://www.wikidata.org/wiki/Q7141
concepts[1].display_name	Cell biology
concepts[2].id	https://openalex.org/C11960822
concepts[2].level	2
concepts[2].score	0.651424765586853
concepts[2].wikidata	https://www.wikidata.org/wiki/Q242736
concepts[2].display_name	Phosphorylation
concepts[3].id	https://openalex.org/C170493617
concepts[3].level	2
concepts[3].score	0.5382537245750427
concepts[3].wikidata	https://www.wikidata.org/wiki/Q208467
concepts[3].display_name	Receptor
concepts[4].id	https://openalex.org/C2909146873
concepts[4].level	4
concepts[4].score	0.42694538831710815
concepts[4].wikidata	https://www.wikidata.org/wiki/Q14912185
concepts[4].display_name	Angiopoietin 2
concepts[5].id	https://openalex.org/C185592680
concepts[5].level	0
concepts[5].score	0.40283000469207764
concepts[5].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[5].display_name	Chemistry
concepts[6].id	https://openalex.org/C86803240
concepts[6].level	0
concepts[6].score	0.27978062629699707
concepts[6].wikidata	https://www.wikidata.org/wiki/Q420
concepts[6].display_name	Biology
concepts[7].id	https://openalex.org/C144133560
concepts[7].level	0
concepts[7].score	0.23678380250930786
concepts[7].wikidata	https://www.wikidata.org/wiki/Q4830453
concepts[7].display_name	Business
concepts[8].id	https://openalex.org/C55493867
concepts[8].level	1
concepts[8].score	0.19424399733543396
concepts[8].wikidata	https://www.wikidata.org/wiki/Q7094
concepts[8].display_name	Biochemistry
concepts[9].id	https://openalex.org/C502942594
concepts[9].level	1
concepts[9].score	0.1464124321937561
concepts[9].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[9].display_name	Cancer research
concepts[10].id	https://openalex.org/C167734588
concepts[10].level	2
concepts[10].score	0.0
concepts[10].wikidata	https://www.wikidata.org/wiki/Q4356503
concepts[10].display_name	VEGF receptors
concepts[11].id	https://openalex.org/C162853370
concepts[11].level	1
concepts[11].score	0.0
concepts[11].wikidata	https://www.wikidata.org/wiki/Q39809
concepts[11].display_name	Marketing
concepts[12].id	https://openalex.org/C2777025900
concepts[12].level	3
concepts[12].score	0.0
concepts[12].wikidata	https://www.wikidata.org/wiki/Q29725
concepts[12].display_name	Vascular endothelial growth factor
keywords[0].id	https://openalex.org/keywords/downstream
keywords[0].score	0.7079275250434875
keywords[0].display_name	Downstream (manufacturing)
keywords[1].id	https://openalex.org/keywords/cell-biology
keywords[1].score	0.6655499935150146
keywords[1].display_name	Cell biology
keywords[2].id	https://openalex.org/keywords/phosphorylation
keywords[2].score	0.651424765586853
keywords[2].display_name	Phosphorylation
keywords[3].id	https://openalex.org/keywords/receptor
keywords[3].score	0.5382537245750427
keywords[3].display_name	Receptor
keywords[4].id	https://openalex.org/keywords/angiopoietin-2
keywords[4].score	0.42694538831710815
keywords[4].display_name	Angiopoietin 2
keywords[5].id	https://openalex.org/keywords/chemistry
keywords[5].score	0.40283000469207764
keywords[5].display_name	Chemistry
keywords[6].id	https://openalex.org/keywords/biology
keywords[6].score	0.27978062629699707
keywords[6].display_name	Biology
keywords[7].id	https://openalex.org/keywords/business
keywords[7].score	0.23678380250930786
keywords[7].display_name	Business
keywords[8].id	https://openalex.org/keywords/biochemistry
keywords[8].score	0.19424399733543396
keywords[8].display_name	Biochemistry
keywords[9].id	https://openalex.org/keywords/cancer-research
keywords[9].score	0.1464124321937561
keywords[9].display_name	Cancer research
language	en
locations[0].id	doi:10.1101/2025.03.17.643633
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S4306402567
locations[0].source.issn
locations[0].source.type	repository
locations[0].source.is_oa	False
locations[0].source.issn_l
locations[0].source.is_core	False
locations[0].source.is_in_doaj	False
locations[0].source.display_name	bioRxiv (Cold Spring Harbor Laboratory)
locations[0].source.host_organization	https://openalex.org/I2750212522
locations[0].source.host_organization_name	Cold Spring Harbor Laboratory
locations[0].source.host_organization_lineage	https://openalex.org/I2750212522
locations[0].license	cc-by
locations[0].pdf_url	https://www.biorxiv.org/content/biorxiv/early/2025/03/20/2025.03.17.643633.full.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1101/2025.03.17.643633
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5086093489
authorships[0].author.orcid
authorships[0].author.display_name	Katharina Uphoff
authorships[0].author_position	first
authorships[0].raw_author_name	Katharina Uphoff
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5043287874
authorships[1].author.orcid	https://orcid.org/0000-0003-4798-7503
authorships[1].author.display_name	Melina Hußmann
authorships[1].author_position	middle
authorships[1].raw_author_name	Melina Hußmann
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5116752043
authorships[2].author.orcid
authorships[2].author.display_name	Dörte Schulte-Ostermann
authorships[2].author_position	middle
authorships[2].raw_author_name	Dörte Schulte-Ostermann
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5113960550
authorships[3].author.orcid
authorships[3].author.display_name	Yvonne Huisman
authorships[3].author_position	middle
authorships[3].raw_author_name	Yvonne Huisman
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5045374933
authorships[4].author.orcid	https://orcid.org/0000-0002-6212-6990
authorships[4].author.display_name	Matthias Mörgelin
authorships[4].author_position	middle
authorships[4].raw_author_name	Matthias Mörgelin
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5014371556
authorships[5].author.orcid	https://orcid.org/0000-0002-5248-8218
authorships[5].author.display_name	Fabian Metzen
authorships[5].author_position	middle
authorships[5].raw_author_name	Fabian Metzen
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5041074020
authorships[6].author.orcid
authorships[6].author.display_name	Fernando Bazán
authorships[6].author_position	middle
authorships[6].raw_author_name	Fernando J Bazan
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5067941504
authorships[7].author.orcid	https://orcid.org/0000-0002-2962-7814
authorships[7].author.display_name	Manuel Koch
authorships[7].author_position	middle
authorships[7].raw_author_name	Manuel Koch
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5056115557
authorships[8].author.orcid	https://orcid.org/0000-0003-3617-8807
authorships[8].author.display_name	Stefan Schulte‐Merker
authorships[8].author_position	last
authorships[8].raw_author_name	Stefan Schulte-Merker
authorships[8].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://www.biorxiv.org/content/biorxiv/early/2025/03/20/2025.03.17.643633.full.pdf
open_access.oa_status	green
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	SVEP1 enables efficient binding of Angiopoietin-2 to the TIE1 receptor, allowing receptor phosphorylation and downstream signaling
has_fulltext	False
is_retracted	False
updated_date	2025-11-23T05:10:03.516525
primary_topic.id	https://openalex.org/T10422
primary_topic.field.id	https://openalex.org/fields/13
primary_topic.field.display_name	Biochemistry, Genetics and Molecular Biology
primary_topic.score	0.9902999997138977
primary_topic.domain.id	https://openalex.org/domains/1
primary_topic.domain.display_name	Life Sciences
primary_topic.subfield.id	https://openalex.org/subfields/1312
primary_topic.subfield.display_name	Molecular Biology
primary_topic.display_name	Angiogenesis and VEGF in Cancer
related_works	https://openalex.org/W1583765404, https://openalex.org/W4214653257, https://openalex.org/W3006566532, https://openalex.org/W2055438207, https://openalex.org/W2521424917, https://openalex.org/W3040203686, https://openalex.org/W4249524554, https://openalex.org/W2349021146, https://openalex.org/W35583307, https://openalex.org/W4398294854
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1101/2025.03.17.643633
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S4306402567
best_oa_location.source.issn
best_oa_location.source.type	repository
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l
best_oa_location.source.is_core	False
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	bioRxiv (Cold Spring Harbor Laboratory)
best_oa_location.source.host_organization	https://openalex.org/I2750212522
best_oa_location.source.host_organization_name	Cold Spring Harbor Laboratory
best_oa_location.source.host_organization_lineage	https://openalex.org/I2750212522
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://www.biorxiv.org/content/biorxiv/early/2025/03/20/2025.03.17.643633.full.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1101/2025.03.17.643633
primary_location.id	doi:10.1101/2025.03.17.643633
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S4306402567
primary_location.source.issn
primary_location.source.type	repository
primary_location.source.is_oa	False
primary_location.source.issn_l
primary_location.source.is_core	False
primary_location.source.is_in_doaj	False
primary_location.source.display_name	bioRxiv (Cold Spring Harbor Laboratory)
primary_location.source.host_organization	https://openalex.org/I2750212522
primary_location.source.host_organization_name	Cold Spring Harbor Laboratory
primary_location.source.host_organization_lineage	https://openalex.org/I2750212522
primary_location.license	cc-by
primary_location.pdf_url	https://www.biorxiv.org/content/biorxiv/early/2025/03/20/2025.03.17.643633.full.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1101/2025.03.17.643633
publication_date	2025-03-20
publication_year	2025
referenced_works	https://openalex.org/W2972662355, https://openalex.org/W2157780537, https://openalex.org/W4399205877, https://openalex.org/W4282598310, https://openalex.org/W2155160938, https://openalex.org/W1970614272, https://openalex.org/W2470520357, https://openalex.org/W2111447897, https://openalex.org/W2028808241, https://openalex.org/W2116028999, https://openalex.org/W4366350942, https://openalex.org/W2009516278, https://openalex.org/W2066763248, https://openalex.org/W2586201220, https://openalex.org/W2517498730, https://openalex.org/W4283644123, https://openalex.org/W2152215024, https://openalex.org/W3177244295, https://openalex.org/W2088475623, https://openalex.org/W2587483777, https://openalex.org/W2161700314, https://openalex.org/W2772071913, https://openalex.org/W2109003285, https://openalex.org/W2616115829, https://openalex.org/W2163301034, https://openalex.org/W4382010962, https://openalex.org/W1984526317, https://openalex.org/W2121717631, https://openalex.org/W2078338839, https://openalex.org/W2172134293, https://openalex.org/W2785293290, https://openalex.org/W3031690692, https://openalex.org/W3005959886, https://openalex.org/W1966821227
referenced_works_count	34
abstract_inverted_index.a	33, 95, 154, 174
abstract_inverted_index.We	98, 152
abstract_inverted_index.an	26
abstract_inverted_index.as	13, 94
abstract_inverted_index.at	177
abstract_inverted_index.by	52, 127
abstract_inverted_index.in	36, 45, 53, 85, 135, 166
abstract_inverted_index.is	74
abstract_inverted_index.of	21, 58, 90, 106, 114, 123, 140, 144
abstract_inverted_index.or	149
abstract_inverted_index.to	9, 19, 121, 147, 160, 173
abstract_inverted_index.we	63
abstract_inverted_index.AKT	145
abstract_inverted_index.The	1
abstract_inverted_index.and	38, 48, 81, 108, 110, 118, 129, 134, 142, 163
abstract_inverted_index.are	7, 16
abstract_inverted_index.due	18
abstract_inverted_index.for	79
abstract_inverted_index.its	183
abstract_inverted_index.key	34
abstract_inverted_index.the	22, 29, 39, 70, 75, 87, 178
abstract_inverted_index.was	43
abstract_inverted_index.ANG2	107, 119, 130, 150
abstract_inverted_index.TIE1	93, 125, 168
abstract_inverted_index.Tie1	42
abstract_inverted_index.also	82
abstract_inverted_index.bind	159
abstract_inverted_index.both	161
abstract_inverted_index.cell	179
abstract_inverted_index.show	83
abstract_inverted_index.site	78
abstract_inverted_index.such	12
abstract_inverted_index.that	4, 15, 69, 84, 101, 111
abstract_inverted_index.turn	136
abstract_inverted_index.with	65, 116
abstract_inverted_index.CCP20	72
abstract_inverted_index.FOXO1	141
abstract_inverted_index.Here,	50
abstract_inverted_index.SVEP1	61, 91, 102, 117, 128, 148, 162
abstract_inverted_index.TIE1,	80, 109, 164
abstract_inverted_index.TIE1.	124
abstract_inverted_index.being	171
abstract_inverted_index.drive	5
abstract_inverted_index.human	47, 71
abstract_inverted_index.leads	120
abstract_inverted_index.mice.	49
abstract_inverted_index.model	155
abstract_inverted_index.shown	44
abstract_inverted_index.site.	97
abstract_inverted_index.where	156
abstract_inverted_index.ANG1/2	157
abstract_inverted_index.Svep1,	32
abstract_inverted_index.alone.	151
abstract_inverted_index.assert	64
abstract_inverted_index.caused	17
abstract_inverted_index.dimers	158
abstract_inverted_index.domain	73
abstract_inverted_index.guided	51
abstract_inverted_index.hdLECs	115
abstract_inverted_index.highly	59
abstract_inverted_index.silico	54
abstract_inverted_index.strong	104
abstract_inverted_index.between	28
abstract_inverted_index.binding	67, 77, 105
abstract_inverted_index.complex	176
abstract_inverted_index.crucial	8
abstract_inverted_index.enables	131
abstract_inverted_index.engages	92
abstract_inverted_index.further	99
abstract_inverted_index.nuclear	138
abstract_inverted_index.present	153
abstract_inverted_index.primary	76
abstract_inverted_index.protein	31, 66
abstract_inverted_index.studies	68
abstract_inverted_index.Abstract	0
abstract_inverted_index.Recently	25
abstract_inverted_index.addition	86
abstract_inverted_index.combined	112
abstract_inverted_index.compared	146
abstract_inverted_index.fragment	89
abstract_inverted_index.mediates	103
abstract_inverted_index.multiple	167
abstract_inverted_index.receptor	41, 169
abstract_inverted_index.secreted	30
abstract_inverted_index.capacity.	185
abstract_inverted_index.confident	60
abstract_inverted_index.diseases,	11
abstract_inverted_index.exclusion	139
abstract_inverted_index.lymphatic	23
abstract_inverted_index.membrane,	180
abstract_inverted_index.molecular	2
abstract_inverted_index.molecules	170
abstract_inverted_index.recruited	172
abstract_inverted_index.regulator	35
abstract_inverted_index.resulting	165
abstract_inverted_index.secondary	96
abstract_inverted_index.signaling	133, 184
abstract_inverted_index.structure	56
abstract_inverted_index.CCP5-EGFL7	88
abstract_inverted_index.activation	126
abstract_inverted_index.amplifying	182
abstract_inverted_index.complexes,	62
abstract_inverted_index.downstream	132
abstract_inverted_index.mechanisms	3
abstract_inverted_index.multimeric	175
abstract_inverted_index.understand	10
abstract_inverted_index.zebrafish,	46
abstract_inverted_index.demonstrate	100
abstract_inverted_index.interaction	27
abstract_inverted_index.lymphedema,	14
abstract_inverted_index.potentially	181
abstract_inverted_index.potentiates	137
abstract_inverted_index.predictions	57
abstract_inverted_index.stimulation	113
abstract_inverted_index.vasculature.	24
abstract_inverted_index.malformations	20
abstract_inverted_index.transmembrane	40
abstract_inverted_index.phosphorylation	122, 143
abstract_inverted_index.AlphaFold-multimer	55
abstract_inverted_index.lymphangiogenesis,	37
abstract_inverted_index.(lymph-)angiogenesis	6
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	9
citation_normalized_percentile.value	0.08477293
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False